Evidence map›Paper›PMID 25249026›Full record

ArticleThe journal of histochemistry and cytochemistry : official journal of the Histochemistry Society2014

Expression of ORAII, a plasma membrane resident subunit of the CRAC channel, in rodent and non-rodent species.

Roberto Guzman, Eliane G Valente, Jim Pretorius, Efrain Pacheco, Meiying Qi, Brian D Bennett, David H Fong, Fen-Fen Lin, Vivian Bi, Helen J McBride

Open access · bronzeAbstract read
In one paragraph

Article in The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. SOCE as a regulator of neuronal activity.The Journal of physiology · 2024
    Review
  7. Neuronal Store-Operated Calcium Channels.Molecular neurobiology · 2023
    Review
  8. A SPLUNC1 Peptidomimetic Inhibits Orai1 and Reduces Inflammation in a Murine Allergic Asthma Model.American journal of respiratory cell and molecular biology · 2022
    Article
  9. The Effects of Insulin-Like Growth Factor I and BTP-2 on Acute Lung Injury.International journal of molecular sciences · 2021
    Article
  10. Article
  11. Article
  12. Review
  13. Targeting Orai1-Mediated Store-Operated CaFrontiers in cell and developmental biology · 2020
    Review
  14. Review
  15. Orai1 Plays a Crucial Role in Central Sensitization by Modulating Neuronal Excitability.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2018
    Article
  16. Orai1 enhances muscle endurance by promoting fatigue-resistant type I fiber content but not through acute store-operated Ca2+ entry.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2016
    Article
  17. Store-Operated Calcium Channels.Physiological reviews · 2015
    Review
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Roberto GuzmanDepartments of Pathology (RG, EGV, JP, EP, MQ), Amgen, Inc. Thousand Oaks, CaliforniaTherapeutic Discovery (FFL, VB), Amgen, Inc. Thousand Oaks, CaliforniaDiscovery Toxicology (HJM), Amgen, Inc. Thousand Oaks, CaliforniaInflammation Research (BDB, DHF), Amgen, Inc. Thousand Oaks, California.
Eliane G ValenteDepartments of Pathology (RG, EGV, JP, EP, MQ), Amgen, Inc. Thousand Oaks, CaliforniaTherapeutic Discovery (FFL, VB), Amgen, Inc. Thousand Oaks, CaliforniaDiscovery Toxicology (HJM), Amgen, Inc. Thousand Oaks, CaliforniaInflammation Research (BDB, DHF), Amgen, Inc. Thousand Oaks, California.
Jim PretoriusDepartments of Pathology (RG, EGV, JP, EP, MQ), Amgen, Inc. Thousand Oaks, CaliforniaTherapeutic Discovery (FFL, VB), Amgen, Inc. Thousand Oaks, CaliforniaDiscovery Toxicology (HJM), Amgen, Inc. Thousand Oaks, CaliforniaInflammation Research (BDB, DHF), Amgen, Inc. Thousand Oaks, California.
Efrain PachecoDepartments of Pathology (RG, EGV, JP, EP, MQ), Amgen, Inc. Thousand Oaks, CaliforniaTherapeutic Discovery (FFL, VB), Amgen, Inc. Thousand Oaks, CaliforniaDiscovery Toxicology (HJM), Amgen, Inc. Thousand Oaks, CaliforniaInflammation Research (BDB, DHF), Amgen, Inc. Thousand Oaks, California.
Meiying QiDepartments of Pathology (RG, EGV, JP, EP, MQ), Amgen, Inc. Thousand Oaks, CaliforniaTherapeutic Discovery (FFL, VB), Amgen, Inc. Thousand Oaks, CaliforniaDiscovery Toxicology (HJM), Amgen, Inc. Thousand Oaks, CaliforniaInflammation Research (BDB, DHF), Amgen, Inc. Thousand Oaks, California.
Brian D BennettDepartments of Pathology (RG, EGV, JP, EP, MQ), Amgen, Inc. Thousand Oaks, CaliforniaTherapeutic Discovery (FFL, VB), Amgen, Inc. Thousand Oaks, CaliforniaDiscovery Toxicology (HJM), Amgen, Inc. Thousand Oaks, CaliforniaInflammation Research (BDB, DHF), Amgen, Inc. Thousand Oaks, California.
David H FongDepartments of Pathology (RG, EGV, JP, EP, MQ), Amgen, Inc. Thousand Oaks, CaliforniaTherapeutic Discovery (FFL, VB), Amgen, Inc. Thousand Oaks, CaliforniaDiscovery Toxicology (HJM), Amgen, Inc. Thousand Oaks, CaliforniaInflammation Research (BDB, DHF), Amgen, Inc. Thousand Oaks, California.
Fen-Fen LinDepartments of Pathology (RG, EGV, JP, EP, MQ), Amgen, Inc. Thousand Oaks, CaliforniaTherapeutic Discovery (FFL, VB), Amgen, Inc. Thousand Oaks, CaliforniaDiscovery Toxicology (HJM), Amgen, Inc. Thousand Oaks, CaliforniaInflammation Research (BDB, DHF), Amgen, Inc. Thousand Oaks, California.
Vivian BiDepartments of Pathology (RG, EGV, JP, EP, MQ), Amgen, Inc. Thousand Oaks, CaliforniaTherapeutic Discovery (FFL, VB), Amgen, Inc. Thousand Oaks, CaliforniaDiscovery Toxicology (HJM), Amgen, Inc. Thousand Oaks, CaliforniaInflammation Research (BDB, DHF), Amgen, Inc. Thousand Oaks, California.
Helen J McBrideDepartments of Pathology (RG, EGV, JP, EP, MQ), Amgen, Inc. Thousand Oaks, CaliforniaTherapeutic Discovery (FFL, VB), Amgen, Inc. Thousand Oaks, CaliforniaDiscovery Toxicology (HJM), Amgen, Inc. Thousand Oaks, CaliforniaInflammation Research (BDB, DHF), Amgen, Inc. Thousand Oaks, California hmcbride@amgen.com.
Amgen (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We determined the expression of ORAI1 protein in rodent and non-rodent tissues using a monoclonal antibody directed against an extracellular loop of the protein. Previous reports using antibodies directed at the C-terminus of ORAI1 have not detected central nervous system (CNS) expression. Our results demonstrate broad tissue expression that includes the CNS using a unique monoclonal antibody specific to an extracellular loop of ORAI1. In addition, we present in situ hybridization (ISH) results using a probe within the middle of the mouse coding region showing CNS expression of Orai1 RNA. We contrast the patterns of rodent and human tissue expression and conclude that rodents have similar expression of ORAI1 in most tissue types when compared to primates, with an important exception being the male reproductive system, where human-specific expression is observed.

Indexed as

AnimalsAntibodies, MonoclonalCalcium ChannelsCell LineCentral Nervous SystemFemaleHumansImmunohistochemistryIn Situ HybridizationMacaca fascicularisMaleMiceMice, Inbred C57BLORAI1 ProteinRatsRats, Sprague-DawleyAntibodies, MonoclonalCalcium ChannelsORAI1 ProteinORAI1 protein, humanOrai1 protein, mouseOrai1 protein, ratRNA, MessengerCRACCRACM1IHCISHmAb266.1ORAI1TMEM142a

Identifiers

PMID25249026
PMCPMC4244304
OpenAlexW2056354805

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.